Cerebellar hallmarks of conditioned preference for cocaine

Pavlovian conditioning tunes the motivational drive of drug-associated stimuli, fostering the probability of those environmental stimuli to promote and trigger drug seeking and taking. Interestingly, different areas in the cerebellum are involved in the formation and long-lasting storage of Pavlovian emotional memory. Very recently, we have shown that conditioned preference for an odour associated with cocaine was directly correlated with cFOS expression in cells at the dorsal region of the granule cell layer of the cerebellar vermis. The main goal of the current investigation was to further extend the description of cFOS-IR patterns in cerebellar circuitry after training mice in a cocaine-odour Pavlovian conditioning procedure, including now the major inputs (the inferior olive and pontine nuclei) and one of the output nuclei (the medial deep nucleus) of the cerebellum. The results showed that the cerebellar hallmark of preference towards an odour cue associated to cocaine is an increase in cFOS expression in the dorsal part of the granule cell layer. cFOS-IR levels expressed in the granule cell layer of mice that did not show cocaine conditioned preference did not differ from the basal levels. Remarkably, mice subjected to a random cocaine-odour pairing procedure (the unpaired group) exhibited higher cFOS-IR in the inferior olive, the pontine nuclei and in the deep medial nucleus. Therefore, our findings suggest that inputs and the output of cerebellar circuitry are enhanced when contingency between the CS+ and cocaine is lacking

Group IVA phospholipase A2 is necessary for the biogenesis of lipid droplets

Lipid droplets (LD) are organelles present in all cell types, consisting of a hydrophobic core of triacylglycerols and cholesteryl esters, surrounded by a monolayer of phospholipids and cholesterol. This work shows that LD biogenesis induced by serum, by long-chain fatty acids, or the combination of both in CHO-K1 cells was prevented by phospholipase A2 inhibitors with a pharmacological profile consistent with the implication of group IVA cytosolic phospholipase A2 (cPLA2α). Knocking down cPLA2α expression with short interfering RNA was similar to pharmacological inhibition in terms of enzyme activity and LD biogenesis. A Chinese hamster ovary cell clone stably expressing an enhanced green fluorescent protein-cPLA2α fusion protein (EGFP-cPLA2) displayed higher LD occurrence under basal conditions and upon LD induction. Induction of LD took place with concurrent phosphorylation of cPLA2α at Ser505. Transfection of a S505A mutant cPLA2α showed that phosphorylation at Ser505 is key for enzyme activity and LD formation. cPLA2α contribution to LD biogenesis was not because of the generation of arachidonic acid, nor was it related to neutral lipid synthesis. cPLA2α inhibition in cells induced to form LD resulted in the appearance of tubulo-vesicular profiles of the smooth endoplasmic reticulum, compatible with a role of cPLA2α in the formation of nascent LD from the endoplasmic reticulum

When Collectivity Makes a Difference: Theoretical and Empirical Insights from Urban and Rural Communities in Colombia

[EN] In this paper, we analyse two Colombian communities using elements of the capability approach. The first, Comuna 8, is an urban community in Medellín, Colombia¿s second largest city. The second community is a Zona de Reserva Campesina (Peasant Farmer Reserve Zone) in the Cabrera municipality, in the Department of Cundinamarca. We explore the reasons why people value being part of a community, along with the collective capabilities that are expanded through community participation. As a product of these capabilities communities plan their own territories, which are examples of collective functionings. Social and environmental conversion factors, as well the historical background of the two communities, are key elements in the analysis. Finally, this research sheds light on individual and collective agency. This agency not only occurs in spaces recognised by Colombian law, but also in areas claimed by the communities themselves.This work was supported by Programa Adsideo 2015, Centro de Cooperacion al Desarrollo, Universitat Politecnica de Valencia. Ayudas Salvador de Madariaga, Subprograma de Movilidad, Plan Estatal de Investigacion Cientifica y Tecnica y de Innovacion 2013-2016.Boni Aristizábal, A.; Millan Franco, GF.; Millan Franco, MA. (2018). When Collectivity Makes a Difference: Theoretical and Empirical Insights from Urban and Rural Communities in Colombia. Journal of Human Development and Capabilities. 19(2):216-231. https://doi.org/10.1080/19452829.2017.1412408S216231192Alkire, S. (2002). Valuing Freedoms. doi:10.1093/0199245797.001.0001Biggeri, M., & Ferrannini, A. (2014). Opportunity Gap Analysis: Procedures and Methods for Applying the Capability Approach in Development Initiatives. Journal of Human Development and Capabilities, 15(1), 60-78. doi:10.1080/19452829.2013.837036Boni, A., & Walker, M. (2016). Universities and Global Human Development. doi:10.4324/9781315742793Crocker, D. A., & Robeyns, I. (s. f.). Capability and Agency. Amartya Sen, 60-90. doi:10.1017/cbo9780511800511.005Deneulin, S. (2014). Wellbeing, Justice and Development Ethics. doi:10.4324/9781315867090Deneulin, S., and S. Alkire. 2009. “A Normative Framework for Development?” InAn Introduction to the Human Development and Capability Approach: Freedom and Agency, edited by S. Deneulin and L. Shahani, 19–31. London: Earthscan.Drydyk, J. (2013). Empowerment, agency, and power. Journal of Global Ethics, 9(3), 249-262. doi:10.1080/17449626.2013.818374Apsan Frediani, A., Boni, A., & Gasper, D. (2014). Approaching Development Projects from a Human Development and Capability Perspective. Journal of Human Development and Capabilities, 15(1), 1-12. doi:10.1080/19452829.2013.879014Gaventa, J. (2006). Finding the Spaces for Change: A Power Analysis. IDS Bulletin, 37(6), 23-33. doi:10.1111/j.1759-5436.2006.tb00320.xHill, J. L. (1996). Psychological sense of community: Suggestions for future research. Journal of Community Psychology, 24(4), 431-438. doi:10.1002/(sici)1520-6629(199610)24:43.0.co;2-tIbrahim, S. S. (2006). From Individual to Collective Capabilities: The Capability Approach as a Conceptual Framework for Self‐help. Journal of Human Development, 7(3), 397-416. doi:10.1080/14649880600815982McMillan, D. W., & Chavis, D. M. (1986). Sense of community: A definition and theory. Journal of Community Psychology, 14(1), 6-23. doi:10.1002/1520-6629(198601)14:13.0.co;2-iRamos-Vidal, I., & Maya-Jariego, I. (2014). Sentido de comunidad, empoderamiento psicológico y participación ciudadana en trabajadores de organizaciones culturales. Psychosocial Intervention, 23(3), 169-176. doi:10.1016/j.psi.2014.04.00

Factors influencing the spread of pertussis in households: a prospective study, Catalonia and Navarre, Spain, 2012 to 2013

We aimed to investigate transmission rates of pertussis in household contacts of cases and factors associated with transmission. A prospective epidemiological study was conducted in 2012 and 2013 to determine the incidence of pertussis among household contacts of reported cases in Catalonia and Navarre, Spain. An epidemiological survey was completed for each case and contact, who were followed for 28 days to determine the source of infection (primary case) and detect the occurrence of secondary cases. Odds ratios (ORs) were used to estimate the effectiveness of vaccination and chemoprophylaxis in preventing new cases, using the formula (1 − OR) × 100. For the 688 primary cases, a total of 2,852 contacts were recorded. The household transmission rate was 16.1% (459/2,852) and rose according to the age (> 18 years) and lack of immunisation of the primary cases, and also the age (0–18 years), family relationship (siblings and children), lack of vaccination and chemoprophylaxis of contacts. Pertussis vaccine effectiveness in preventing new cases was 65.0% (95% confidence interval (CI): 11.6 to 86.2) for full vaccination (≥ 4 doses) and 59.7% (95% CI: −6.8 to 84.8) for incomplete vaccination (< 4 doses). The effectiveness of chemoprophylaxis was 62.1% (95% CI: 40.3 to 75.9). To reduce household transmission, contacts should be investigated to detect further cases and to administer chemoprophylaxis. The current vaccination status of cases and contacts can reduce household transmission.This study was supported by the Ministry of Science and Innovation, Institute of Health Carlos III (Project PI11/02557) and Fondo Europeo de Desarrollo Regional (FEDER-Una manera de hacer Europa)

Thrombectomy within 8 hours after symptom onset in ischemic stroke

BACKGROUND: We aimed to assess the safety and efficacy of thrombectomy for the treatment of stroke in a trial embedded within a population-based stroke reperfusion registry. METHODS: During a 2-year period at four centers in Catalonia, Spain, we randomly assigned 206 patients who could be treated within 8 hours after the onset of symptoms of acute ischemic stroke to receive either medical therapy (including intravenous alteplase when eligible) and endovascular therapy with the Solitaire stent retriever (thrombectomy group) or medical therapy alone (control group). All patients had confirmed proximal anterior circulation occlusion and the absence of a large infarct on neuroimaging. In all study patients, the use of alteplase either did not achieve revascularization or was contraindicated. The primary outcome was the severity of global disability at 90 days, as measured on the modified Rankin scale (ranging from 0 [no symptoms] to 6 [death]). Although the maximum planned sample size was 690, enrollment was halted early because of loss of equipoise after positive results for thrombectomy were reported from other similar trials. RESULTS Thrombectomy reduced the severity of disability over the range of the modified Rankin scale (adjusted odds ratio for improvement of 1 point, 1.7; 95% confidence interval [CI], 1.05 to 2.8) and led to higher rates of functional independence (a score of 0 to 2) at 90 days (43.7% vs. 28.2%; adjusted odds ratio, 2.1; 95% CI, 1.1 to 4.0). At 90 days, the rates of symptomatic intracranial hemorrhage were 1.9% in both the thrombectomy group and the control group (P = 1.00), and rates of death were 18.4% and 15.5%, respectively (P = 0.60). Registry data indicated that only eight patients who met the eligibility criteria were treated outside the trial at participating hospitals. CONCLUSIONS: Among patients with anterior circulation stroke who could be treated within 8 hours after symptom onset, stent retriever thrombectomy reduced the severity of post-stroke disability and increased the rate of functional independence

Measurement of the inclusive isolated prompt photon cross section in pp collisions at sqrt(s) = 7 TeV with the ATLAS detector

A measurement of the cross section for the inclusive production of isolated prompt photons in pp collisions at a center-of-mass energy root s = 7 TeV is presented. The measurement covers the pseudorapidity ranges vertical bar eta(gamma)vertical bar < 1: 37 and 1: 52 <= vertical bar eta(gamma)vertical bar < 1: 81 in the transverse energy range 15 <= E-T(gamma) < 100 GeV. The results are based on an integrated luminosity of 880 nb(-1), collected with the ATLAS detector at the Large Hadron Collider. Photon candidates are identified by combining information from the calorimeters and from the inner tracker. Residual background in the selected sample is estimated from data based on the observed distribution of the transverse isolation energy in a narrow cone around the photon candidate. The results are compared to predictions from next-to-leading-order perturbative QCD calculations

Jet energy measurement with the ATLAS detector in proton-proton collisions at sqrt(s) = 7 TeV

The jet energy scale (JES) and its systematic uncertainty are determined for jets measured with the ATLAS detector at the LHC in proton-proton collision data at a centre-of-mass energy of sqrt(s) = 7 TeV corresponding to an integrated luminosity of 38 inverse pb. Jets are reconstructed with the anti-kt algorithm with distance parameters R=0.4 or R=0.6. Jet energy and angle corrections are determined from Monte Carlo simulations to calibrate jets with transverse momenta pt > 20 GeV and pseudorapidities eta 50 GeV after a dedicated correction for this effect. The JES is validated for jet transverse momenta up to 1 TeV to the level of a few percent using several in situ techniques by comparing a well-known reference such as the recoiling photon pt, the sum of the transverse momenta of tracks associated to the jet, or a system of low-pt jets recoiling against a high-pt jet. More sophisticated jet calibration schemes are presented based on calorimeter cell energy density weighting or hadronic properties of jets, providing an improved jet energy resolution and a reduced flavour dependence of the jet response. The JES systematic uncertainty determined from a combination of in situ techniques are consistent with the one derived from single hadron response measurements over a wide kinematic range. The nominal corrections and uncertainties are derived for isolated jets in an inclusive sample of high-pt jets

Search for the Standard Model Higgs boson in the decay channel H->ZZ(*)->4l with the ATLAS detector

A search for the Standard Model Higgs boson in the decay channel H -> ZZ(()*()) l(+)l(-)l'l'(-), where l = e, mu, is presented. Proton-proton collision data at root s = 7 TeV recorded with the ATLAS detector and corresponding to an average integrated luminosity of 2.1 fb(-1) are compared to the Standard Model expectations. Upper limits on the production cross section of a Standard Model Higgs boson with a mass between 110 and 600 GeV are derived. The observed (expected) 95% confidence level upper limit on the production cross section for a Higgs boson with a mass of 194 GeV, the region with the best expected sensitivity for this search, is 0.99 (1.01) times the Standard Model prediction. The Standard Model Higgs boson is excluded at 95% confidence level in the mass ranges 191-197, 199-200 and 214-224 GeV

Diplopia Is Frequent and Associated with Motor and Non-Motor Severity in Parkinson’s Disease: Results from the COPPADIS Cohort at 2-Year Follow-Up

[Background and objective] Diplopia is relatively common in Parkinson’s disease (PD) but is still understudied. Our aim was to analyze the frequency of diplopia in PD patients from a multicenter Spanish cohort, to compare the frequency with a control group, and to identify factors associated with it.[Patients and Methods] PD patients who were recruited from January 2016 to November 2017 (baseline visit; V0) and evaluated again at a 2-year ± 30 days follow-up (V2) from 35 centers of Spain from the COPPADIS cohort were included in this longitudinal prospective study. The patients and controls were classified as “with diplopia” or “without diplopia” according to item 15 of the Non-Motor Symptoms Scale (NMSS) at V0, V1 (1-year ± 15 days), and V2 for the patients and at V0 and V2 for the controls.[Results] The frequency of diplopia in the PD patients was 13.6% (94/691) at V0 (1.9% in controls [4/206]; p < 0.0001), 14.2% (86/604) at V1, and 17.1% (86/502) at V2 (0.8% in controls [1/124]; p < 0.0001), with a period prevalence of 24.9% (120/481). Visual hallucinations at any visit from V0 to V2 (OR = 2.264; 95%CI, 1.269–4.039; p = 0.006), a higher score on the NMSS at V0 (OR = 1.009; 95%CI, 1.012–1.024; p = 0.015), and a greater increase from V0 to V2 on the Unified Parkinson’s Disease Rating Scale–III (OR = 1.039; 95%CI, 1.023–1.083; p < 0.0001) and Neuropsychiatric Inventory (OR = 1.028; 95%CI, 1.001–1.057; p = 0.049) scores were independent factors associated with diplopia (R2 = 0.25; Hosmer and Lemeshow test, p = 0.716).[Conclusions] Diplopia represents a frequent symptom in PD patients and is associated with motor and non-motor severity.Martínez-Martin P. has received honoraria from National School of Public Health (ISCIII), Editori-al Viguera and Takeda Pharmaceuticals for lecturing in courses, and from the International Parkinson and Movement Disorder Society (MDS) for management of the Program on Rating Scales. Mir P. has received honoraria from AbbVie, Abbott, Allergan, Bial, Merz, UCB, and Zambon and have received grants from the Spanish Ministry of Economy and Competitiveness [PI16/01575], co-founded by ISCIII (Subdirección General de Evaluación y Fomento de la Investigación) and by Fondo Europeo de Desarrollo Regional (FEDER), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía [CVI-02526, CTS-7685], the Consejería de Salud y Bienestar Social de la Junta de Andalucía [ PI-0437-2012, PI-0471-2013], the Sociedad Andaluza de Neurología, the Jacques and Gloria Gossweiler Foundation, the Fundación Alicia Koplowitz, the Fundación Mutua Madrileña.Peer reviewe